Cargando…

Mutated trimeric RBD vaccines: a platform against variants of concern

Detalles Bibliográficos
Autores principales:	Aparicio, Belén, Lasarte, Juan J., Sarobe, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098232/ https://www.ncbi.nlm.nih.gov/pubmed/37055392 http://dx.doi.org/10.1038/s41392-023-01426-3

Ejemplares similares

Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma
por: Silva, Leyre, et al.
Publicado: (2020)

SARS-CoV-2 mutations, vaccines, and immunity: implication of variants of concern
por: Noh, Ji Yun, et al.
Publicado: (2021)

Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies
por: Aparicio, Belén, et al.
Publicado: (2023)

Erratum: Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies
por: Aparicio, Belén, et al.
Publicado: (2023)

Structural insights into the Omicron spike trimer: tackling the challenges of continuously evolving SARS-CoV-2 variants
por: Ou, Junxian, et al.
Publicado: (2022)

RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
por: Liang, Qingtai, et al.
Publicado: (2022)

Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2
por: Liang, Yu, et al.
Publicado: (2022)

Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
por: Repáraz, David, et al.
Publicado: (2022)

Boosting with variant-matched vaccines: an opportunity to win the race against Omicron
por: Wang, Jiayu, et al.
Publicado: (2022)

Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS‐CoV‐2 and variants
por: Su, Peng, et al.
Publicado: (2022)

A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants
por: Zhang, Jing, et al.
Publicado: (2022)

Highlight: Ancient Human Polymorphisms Linked to Modern-Day Health Concerns for Native Americans
por: McGrath, Casey
Publicado: (2019)

Design of a tailor‐made platform for syngas bioconversion into polyhydroxybutyrate
por: Narancic, Tanja, et al.
Publicado: (2017)

How will previous infection or current vaccination strategies protect us from future SARS‐CoV‐2 variant infections?
por: Monteiro, Olivia
Publicado: (2022)

A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern
por: Yang, Jingyi, et al.
Publicado: (2022)

Adenine base editing to mimic or correct disease mutations in rodents
por: Ren, Ruotong, et al.
Publicado: (2018)

Variant constraint by mRNA vaccines
por: Bordon, Yvonne
Publicado: (2021)

SARS-CoV-2 Variants of Concern Delta: a great challenge to prevention and control of COVID-19
por: Li, Maochen, et al.
Publicado: (2021)

Explorative probes and biomarkers, chronic Salmonella infections and future vaccines
por: Michán, Carmen, et al.
Publicado: (2012)

A bivalent recombinant vaccine: a promising strategy against both SARS-CoV-2 variants and wild type of the virus
por: Wang, Junzhi
Publicado: (2021)

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern
por: Deshpande, Ashlesha, et al.
Publicado: (2021)

Struggling to get a universal meningococcal vaccine and novel uses for bacterial toxins in cancer treatment
por: Daniels, Craig, et al.
Publicado: (2010)

Coronavirus Variants—Will New mRNA Vaccines Meet the Challenge?
por: Welsh, Jennifer
Publicado: (2021)

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern
por: Komori, Mai, et al.
Publicado: (2023)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice
por: Sun, Wenqiang, et al.
Publicado: (2021)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

A promising vaccine candidate against COVID-19
por: Wang, Xiwei, et al.
Publicado: (2020)

Timing vaccination against SARS-CoV-2
por: Barnoud, Coline, et al.
Publicado: (2021)

Role of antibodies in vaccine-mediated protection against tuberculosis
por: Dieli, Francesco, et al.
Publicado: (2022)

Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination
por: Repáraz, David, et al.
Publicado: (2022)

RBD(206)-sc-dimer induced robust cross-neutralization against SARS-CoV-2 and variants of concern
por: Zhou, Chuge, et al.
Publicado: (2021)

Fighting the enemy: one health approach against microbial resistance
por: Udaondo, Zulema, et al.
Publicado: (2020)

Microbial antibiotics take the lead in the fight against plant pathogens
por: Roca, Amalia, et al.
Publicado: (2022)

Highlight: Tiny Bacterial Genome Opens a Huge Mystery: AT Mutational Bias in Hodgkinia
por: Venton, Danielle
Publicado: (2012)

Synonymous but Not Equal: A Special Section and Virtual Issue on Phenotypic Effects of Synonymous Mutations
por: McGrath, Casey
Publicado: (2021)

Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity
por: Provine, Nicholas M., et al.
Publicado: (2022)

Immunological study of COVID-19 vaccine candidate based on recombinant spike trimer protein from different SARS-CoV-2 variants of concern
por: Rudi, Erika, et al.
Publicado: (2022)

Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
por: Aparicio, Belén, et al.
Publicado: (2021)

Real Nano “Light Vaccine” Will Benefit to COVID-19 Pandemic Control
por: Yang, Jianshe
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4nl1g1ij61q7m03jorm0vvc5ko